TCIM
RIGL icon

TIAA CREF Investment Management’s Rigel Pharmaceuticals RIGL Stock Holding History

TIAA CREF Investment Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$987K Buy
38,396
+7,589
+25% +$174K ﹤0.01% 2323
2018
Q4 		$709K Sell
30,807
-233
-0.8% -$6.58K ﹤0.01% 2425
2018
Q3 		$996K Sell
31,040
-2,446
-7% -$73.4K ﹤0.01% 2420
2018
Q2 		$948K Buy
33,486
+802
+2% +$28.5K ﹤0.01% 2514
2018
Q1 		$1.16M Sell
32,684
-519
-2% -$20.8K ﹤0.01% 2362
2017
Q4 		$1.29M Buy
33,203
+2,689
+9% +$102K ﹤0.01% 2343
2017
Q3 		$775K Sell
30,514
-16,801
-36% -$409K ﹤0.01% 2639
2017
Q2 		$1.29M Buy
47,315
+2,260
+5% +$61.9K ﹤0.01% 2421
2017
Q1 		$1.49M Sell
45,055
-3,329
-7% -$84.8K ﹤0.01% 2308
2016
Q4 		$1.15M Sell
48,384
-27,159
-36% -$778K ﹤0.01% 2452
2016
Q3 		$2.77K Buy
75,543
+2,689
+4% +$77.1K ﹤0.01% 1996
2016
Q2 		$1.63M Sell
72,854
-11,297
-13% -$281K ﹤0.01% 2248
2016
Q1 		$1.75M Buy
84,151
+15,015
+22% +$370K ﹤0.01% 2157
2015
Q4 		$2.1M Buy
69,136
+6,130
+10% +$186K ﹤0.01% 2115
2015
Q3 		$1.56M Sell
63,006
-6,350
-9% -$190K ﹤0.01% 2298
2015
Q2 		$2.23M Buy
69,356
+32,931
+90% +$1.26M ﹤0.01% 2236
2015
Q1 		$1.3M Hold
36,425
– – ﹤0.01% 2478
2014
Q4 		$827K Sell
36,425
-1,903
-5% -$38.5K ﹤0.01% 2759
2014
Q3 		$744K Sell
38,328
-1,055
-3% -$29.8K ﹤0.01% 2799
2014
Q2 		$1.43M Buy
39,383
+926
+2% +$31.5K ﹤0.01% 2500
2014
Q1 		$1.49M Sell
38,457
-1,084
-3% -$38.6K ﹤0.01% 2411
2013
Q4 		$1.13M Sell
39,541
-1,960
-5% -$57.5K ﹤0.01% 2597
2013
Q3 		$1.49M Sell
41,501
-9,226
-18% -$337K ﹤0.01% 2390
2013
Q2 		$1.69M Buy
+50,727
New +$2.3M ﹤0.01% 2272

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

TIAA CREF Investment Management's RIGL Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Rigel Pharmaceuticals (RIGL) stake by 25% in Q1 2019, buying an estimated $174K and bringing the position to 38,396 shares worth $987K. The position accounts for ﹤0.01% of the portfolio, ranked #2323.

TIAA CREF Investment Management first reported a position in RIGL in Q2 2013 and has held it in 24 quarters since. The position peaked at $2.23M in Q2 2015. 131 funds tracked by Wall St. Rank hold RIGL as of Q1 2019.

  • TIAA CREF Investment Management held 38,396 shares of Rigel Pharmaceuticals worth $987K as of Q1 2019.
  • TIAA CREF Investment Management bought 7,589 Rigel Pharmaceuticals shares in Q1 2019, an estimated $174K.
  • Rigel Pharmaceuticals made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2323 holding.
  • TIAA CREF Investment Management first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Rigel Pharmaceuticals position peaked at $2.23M in Q2 2015.
  • 131 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.